Evidence map›Paper›PMID 34869423›Full record

ArticleFrontiers in medicine2021

Substance P/ Neurokinin-1 Receptor, Trigeminal Ganglion, Latency, and Coronavirus Infection-Is There Any Link?

Riffat Mehboob, Maher Kurdi, Ahmed Bamaga, Njoud Aldardeir, Hisham Nasief, Leena H Moshref, Taghreed Alsinani, Almotasimbellah O Rayes, Reem H Jabbad

Open access · goldAbstract read
In one paragraph

Article in Frontiers in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Systematic Down-Selection of Repurposed Drug Candidates for COVID-19.International journal of molecular sciences · 2022
    Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 3 countries.

Riffat MehboobFaculty of Allied Health Sciences, The University of Lahore, Lahore, Pakistan.
Maher KurdiDepartment of Pathology, Faculty of Medicine, King Abdulaziz University, Rabigh, Saudi Arabia.
Ahmed BamagaNeurology Division, Department of Pediatrics, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
Njoud AldardeirFaculty of Education, University of Ottawa, Ottawa, ON, Canada.
Hisham NasiefDepartment of Obstetrics and Gynecology, Faculty of Medicine, Jeddah, Saudi Arabia.
Leena H MoshrefDepartment of Surgery, Doctor Soliman Fakeeh Hospital, Jeddah, Saudi Arabia.
Taghreed AlsinaniDivision of Neurosurgery, King Fahad General Hospital, Jeddah, Saudi Arabia.
Almotasimbellah O RayesDepartment of Obstetrics and Gynecology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
Reem H JabbadDepartment of Medicine, King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia.
King Abdulaziz University · SAJeddah University · SAKing Fahad Hospital Jeddah · SAKing Fahd Armed Forces Hospital · SASoliman Fakeeh Hospital · SAUniversity of Lahore · PKUniversity of Ottawa · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Novel Severe Acute Respiratory Syndrome-Corona Virus-2 infection (SARS-CoV-2) is an acute respiratory and infectious disease. This perspective aims to provide a basic understanding of the inflammation caused by SARS-CoV-2 and its relation to the trigeminal ganglion (TG). The virus enters through the mucous membranes of the orofacial region and reaches the TG, where it resides and takes control of its peptides including Substance P (SP). SP is the main neuropeptide, neuromodulator, and neuro-hormone of TG, associated with nociception and inflammation under noxious stimulus. SP release is triggered and, consequently, affects the immune cells and blood vessels to release the mediators for inflammation. Hence, cytokine storm is initiated and causes respiratory distress, bronchoconstriction, and death in complicated cases. Neurokinin-1 Receptor (NK-1R) is the receptor for SP and its antagonists, along with glucocorticoids, may be used to alleviate the symptoms and treat this infection by blocking this nociceptive pathway. SP seems to be the main culprit involved in the triggering of inflammatory pathways in SARS-CoV-2 infection. It may have a direct association with cardio-respiratory rhythm, sleep-wake cycle, nociception, and ventilatory responses and regulates many important physiological and pathological functions. Its over-secretion should be blocked by NK-1R antagonist. However, experimental work leading to clinical trials are mandatory for further confirmation. Here, it is further proposed that there is a possibility of latency in SARS-CoV-2 virus infection if it is acting through TG, which is the main site for other viruses that become latent.

Indexed as

coronavirusinfectious diseaserespiratory illnessSubstance P/ Neurokinin-1 Receptortrigeminal ganglion

Identifiers

PMID34869423
PMCPMC8637107
OpenAlexW3217713676

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.